PD-L1: A Biomarker for Cancer Immunotherapy? Read More Stories May 10, 2015 Tags: Oncology, Cancer Immunotherapy Read More Stories The American Society of Clinical Oncology Genentech ASCO spotlights what’s next in cancer research and treatment. We’ve gathered perspectives from around the cancer community on topics people will be talking about at the meeting. PD-L1/PD-1 Pathway: A Security Checkpoint Genentech Dr. Dan Chen explains how cancer immunotherapy helps break the cellular camouflage of PD-L1. The Cancer-Immunity Cycle Genentech The cancer immunity cycle has become the framework for cancer immunotherapy research. Learn the steps of the cycle here.
